| Date | Title | Description |
| 10.07.2026 | Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8® | ReActiv8® Restorative NeurostimulationTM demonstrated statistically significant and clinically meaningful superiority vs. standard of care in all primary and secondary measures of disability, pain and quality of life
Safety profile consiste... |
| 10.07.2026 | Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv8 | Mainstay Medical Holdings plc today announced that the International Society for the Advancement of Spine Surgery (ISASS) has issued recommendations and coverage criteria for the use of restorative neurostimulation for the treatment of chro... |
| 10.07.2026 | Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield | Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic lo... |
| 20.03.2024 |
Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up | Groundbreaking ReActiv8-B study supports the long-term efficacy, safety and durability of ReActiv8® Restorative NeurostimulationTM for the treatment of intractable Chronic Low Back Pain
Mainstay Medical Holdings plc today announced the p... |
| 13.03.2024 |
Mainstay Medical Announces Publication of Clinical Results Comparing Older Patients and Younger Patients | Efficacy of ReActiv8® Restorative Neurostimulation™ shows no statistically or clinically meaningful differences between older and younger patient populations.
Mainstay Medical Holdings plc today announced the publication of a pooled anal... |
| 26.02.2024 |
Mainstay Medical Announces US$125 Million Equity Financing Transaction | Funding to accelerate commercial growth and expand clinical and health economic evidence for ReActiv8® Restorative NeuromodulationTM System
Mainstay Medical Holdings plc today announced an equity financing in which it will receive gross ... |
| 13.02.2024 |
Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation SystemTM | U.S. patients implanted with ReActiv8 now eligible for full-body MRI scans
Mainstay Medical Holdings plc today announced that the U.S. Food and Drug Administration (FDA) has approved full-body MRI conditional labeling for the ReActiv8® R... |
| 29.08.2023 |
Mainstay Medical Announces Completion of Enrollment of RESTORE Clinical Trial of ReActiv8® in the United States | Randomized controlled clinical trial expected to validate effectiveness of ReActiv8® Restorative NeurostimulationTM vs. optimal medical management
Mainstay Medical Holdings plc today announced the completion of enrollment in its RESTORE ... |
| 21.07.2023 |
Mainstay Medical Announces Publication of Three-Year Clinical Trial Data from Post-Market Clinical Follow-up Registry of ReActiv8® in the United Kingdom | Further real-world evidence supporting the efficacy and use of ReActiv8® Restorative NeurostimulationTM for the treatment of intractable Chronic Low Back Pain
Mainstay Medical Holdings plc today announced the publication of three-year cl... |
| 09.03.2021 |
Mainstay Medical Announces Commercial Launch of ReActiv8® in Australia | Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced the commercial launch in Australia of ReActiv8®, its implantable neurostimulation system to treat chronic low back pain.
“Launching ReActiv8, our Restorative Neuro... |
| 08.03.2021 | Mainstay Medical announces commercial launch of ReActiv8® in Australia | Dublin, Ireland: 8 March 2021 – Mainstay Medical Holdings plc today announced the commercial launch in Australia of ReActiv8®, its implantable neurostimulation system to treat chronic low back pain. |
| 16.02.2021 | Mainstay Medical Holdings plc announced that it has received $108 million in funding from Ally Bridge Group, KCK Group, Sofinnova Partners SAS, Fountain Healthcare Partners, and another investor | On February 16, 2021, Mainstay Medical Holdings plc closed the transaction. The company has raised gross proceeds of $108 million in equity financing led by new investors Ally Bridge Group, Sofinnova Crossover I managed by existing investor... |
| 16.02.2021 |
Mainstay Medical Announces US$108 Million Equity Financing Transaction | Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced the closing of an equity financing in which it raised gross proceeds of US$108 million. Mainstay intends to use the funds to support the company’s commercial launch... |
| 16.02.2021 | Mainstay Medical announces US$ 108 million equity financing transaction | Funding to support U.S. commercial launch and global expansion |
| 16.02.2021 | Ally Bridge Group Co-leads Mainstay Medical’s $108 Million Equity Financing
Contacts | Funding to support U.S. commercial launch and global expansion
DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced the closing of an equity financing in which it raised gross proceeds of US$10... |
| 16.02.2021 | Mainstay Medical Announces US$108 Million Equity Financing Transaction | DUBLIN–(BUSINESS WIRE)–Feb 16, 2021–
Mainstay Medical Holdings plc (“ Mainstay ” or the “ Company ”) today announced the closing of an equity financing in which it raised gross proceeds of US$108 million. Mainstay intends to use the funds t... |
| 16.02.2021 | Mainstay Medical Receives US$108M Equity Financing | Mainstay Medical Holdings, a Dublin, Ireland-based medical device company focused on commercializing an innovative implantable restorative neurostimulation system for people with disabling mechanical Chronic Low Back Pain, closed an equity ... |
| 16.02.2021 | Mainstay Medical Announces US$108 Million Equity Financing Transaction | Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced the closing of an equity financing in which it raised gross proceeds of US$108 million. Mainstay intends to use the funds to support the company’s commercial launch... |
| 25.01.2021 | Mainstay Medical announces key strategic Vice President hires to drive global commercial expansion | Appointments to support upcoming commercial launch of ReActiv8 in the US and foster further growth in Europe and Australia |
| 22.06.2020 | Mainstay Medical announces US FDA approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain | Dublin, Ireland: 22 June 2020 – Mainstay Medical Holdings plc today announced that the US Food and Drug Administration (FDA) has approved the Company’s Premarket Approval (PMA) application for ReActiv8®, its implantable neurostimulation sys... |
| 08.06.2020 | Mainstay Medical announces reimbursement approval for ReActiv8 in Australia | Dublin, Ireland: 8 June 2020 – Mainstay Medical Holdings plc today announced that ReActiv8, its implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, has been approved for inclusion in the Prostheses List... |
| 17.01.2020 | PREDICT-LAA trial enrolls first patient | Ghent, Belgium: 17 January 2020 – FEops, a leader in personalized predictive planning for structural heart interventions, is proud to announce that today the first patient has been enrolled in the physician-initiated PREDICT-LAA trial. The ... |
| 06.12.2019 | Mainstay Medical announces regulatory approval from Australian Therapeutic Goods Administration (TGA) for ReActiv8 | Dublin, Ireland: 6 December 2019 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and Euronext Growth operated by Euronext Dublin: MSTY.IE), today announced that it has received regulatory approval from the Australian Therapeut... |
| 01.10.2019 | Mainstay Medical announces acceptance for filing by US FDA of Pre-Market Approval (PMA) Application for ReActiv8 | Dublin, Ireland: 1 October 2019 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and Euronext Growth of Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulatio... |
| 30.07.2019 | Mainstay Medical announces completion of financing transactions | • Funds to be used to support PMA process for ReActiv8® in US and to further European commercial validation efforts |
| 26.06.2019 | Mainstay Medical announces completion of pre-submission meeting with FDA regarding Pre-Market Approval (PMA) application for ReActiv8 | Dublin, Ireland: 26 June 2019 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and Euronext Growth operated by Euronext Dublin (MSTY.IE), a medical device company focused on bringing to market ReActiv8, an implantable restorati... |
| 18.04.2019 | Mainstay Medical provides company update and publishes 2018 full year results | Dublin, Ireland: 18 April 2019 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and Euronext Growth operated by Euronext Dublin (MSTY.IE), a medical device company focused on bringing to market ReActiv8, an implantable restorat... |
| 21.09.2018 | Mainstay Medical announces 2018 half-year financial results and update | Dublin, Ireland: 21 September 2018 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on commercializing ReActiv8®, an implantable restorative neurostimulation syste... |
| 20.08.2018 | Mainstay Medical announces the appointment of Matthew Onaitis as Chief Financial Officer | Dublin, Ireland: 20 August 2018 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation syste... |
| 09.07.2018 | Mainstay Medical announces the completion of all implants in the ReActiv8-B Study | Dublin, Ireland: 9 July 2018 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8, an implantable restorative neurostimulation system to... |
| 20.06.2018 | Mainstay Medical appoints Wolfgang Frisch as VP and Managing Director for Germany | Dublin, Ireland: 20 June 2018 – Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restora... |
| 05.04.2018 | Mainstay’s Update on Regulatory Application for ReActiv8 in Australia | Dublin, Ireland: 5 April 2018 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurosti... |
| 15.02.2018 | Mainstay Medical publishes 2017 full year results | Dublin, Ireland: 15 February 2018 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8, an implantable restorative neuro... |
| 15.02.2018 | Mainstay Medical announces € 30 million financing new capital to complete US Pivotal ReActiv8-B clinical study and advance european commercialization | Dublin, Ireland: 15 February 2018 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation... |
| 23.01.2018 | Mainstay confirms its continued eligibility to the PEA-PME | Dublin, Ireland: 23 January 2018 – Mainstay Medical International plc (listed on Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE) confirms today its continued eligibility to the PEA-PME (French equity savings plan for f... |
| 11.12.2017 | Mainstay Medical announces positive outcome of interim analysis | Dublin, Ireland: 11 December 2017 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neur... |
| 23.03.2017 | Mainstay Medical Publishes 2016 Full Year Results and Business Update | 23 March 2017 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system ... |
| 01.02.2017 | Mainstay Medical starts commercialization of ReActiv8® for the treatment of Chronic Low Back Pain | Dublin, Ireland: 1 February 2017 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation ... |
| 24.01.2017 | Mainstay confirms its continued eligibility to the PEA-PME | Dublin, Ireland: 24 January 2017 – Mainstay Medical International plc (listed on Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE) confirms today its continued eligibility to the PEA-PME (French equity savings plan for f... |
| 12.01.2017 | Mainstay Medical Applies for Approval to Market ReActiv8® in Australia | Dublin, Ireland: 12 January 2017 – Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8, an implantable neurostimulation s... |
| 01.05.2014 | Report: Mainstay Medical’s IPO raises $25M | Mainstay Medical‘s (MSTY.PA) European initial public offering reeled in about $25 million (€18 million) and made the spinal implant maker the 1st medtech company to float an IPO in Paris and the 1st company to attempt a dual flotation in Pa... |
| - | Mainstay Medical | “Mainstay Medical is improving quality of life for patients with chronic low back pain through innovative restorative treatment medical device solutions.” |
